S
1.17
0.02 (1.74%)
| 前收盘价格 | 1.15 |
| 收盘价格 | 1.19 |
| 成交量 | 34,103 |
| 平均成交量 (3个月) | 41,106 |
| 市值 | 3,703,997 |
| 价格/销量 (P/S) | 2.19 |
| 股市价格/股市净资产 (P/B) | 5.59 |
| 52周波幅 | |
| 利润日期 | 12 Aug 2025 - 18 Aug 2025 |
| 营业利益率 (TTM) | -1,378.09% |
| 稀释每股收益 (EPS TTM) | -12.28 |
| 季度收入增长率 (YOY) | 5,268.80% |
| 总债务/股东权益 (D/E MRQ) | 13.66% |
| 流动比率 (MRQ) | 1.03 |
| 营业现金流 (OCF TTM) | -11.62 M |
| 杠杆自由现金流 (LFCF TTM) | -7.73 M |
| 资产报酬率 (ROA TTM) | -176.75% |
| 股东权益报酬率 (ROE TTM) | -714.97% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Sonnet BioTherapeutics Holdings | 混合的 | 看涨 |
AIStockmoo 评分
0.0
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.00 |
|
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.53% |
| 机构持股比例 | 5.24% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Carolina Wealth Advisors, Llc | 31 Dec 2024 | 32 |
| 52周波幅 | ||
| 中 | 20.00 (1,609.40%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Chardan Capital | 07 Apr 2025 | 20.00 (1,609.40%) | 购买 | 1.20 |
| 28 Mar 2025 | 20.00 (1,609.40%) | 购买 | 1.31 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合